BidaskClub upgraded shares of LivaNova (NASDAQ:LIVN) from a hold rating to a buy rating in a research note published on Wednesday.
A number of other analysts have also issued reports on the company. UBS Group initiated coverage on LivaNova in a research note on Tuesday, November 27th. They set a neutral rating and a $105.00 price objective on the stock. Zacks Investment Research upgraded LivaNova from a strong sell rating to a hold rating in a research note on Wednesday, January 2nd. BTIG Research restated a hold rating on shares of LivaNova in a research note on Wednesday, November 21st. Finally, ValuEngine lowered LivaNova from a strong-buy rating to a buy rating in a research note on Wednesday, November 28th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. LivaNova presently has an average rating of Buy and a consensus target price of $122.20.
NASDAQ:LIVN opened at $99.84 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65. LivaNova has a 52-week low of $79.96 and a 52-week high of $131.54. The firm has a market cap of $4.82 billion, a P/E ratio of 30.16, a P/E/G ratio of 2.88 and a beta of 0.87.
In other LivaNova news, insider Alistair Simpson sold 450 shares of the company’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $90.10, for a total value of $40,545.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction dated Monday, December 17th. The stock was sold at an average price of $92.12, for a total value of $138,180.00. The disclosure for this sale can be found here. Insiders sold a total of 6,450 shares of company stock worth $606,015 over the last 90 days. Corporate insiders own 0.41% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of LIVN. Federated Investors Inc. PA boosted its holdings in shares of LivaNova by 1,514.3% in the 3rd quarter. Federated Investors Inc. PA now owns 557,386 shares of the company’s stock worth $69,099,000 after purchasing an additional 522,859 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of LivaNova by 7.3% in the 3rd quarter. BlackRock Inc. now owns 5,787,930 shares of the company’s stock worth $717,530,000 after purchasing an additional 394,915 shares in the last quarter. Morgan Stanley boosted its holdings in shares of LivaNova by 230.8% in the 3rd quarter. Morgan Stanley now owns 510,953 shares of the company’s stock worth $63,343,000 after purchasing an additional 356,476 shares in the last quarter. Rehmann Capital Advisory Group boosted its holdings in shares of LivaNova by 12,226.6% in the 3rd quarter. Rehmann Capital Advisory Group now owns 303,974 shares of the company’s stock worth $2,452,000 after purchasing an additional 301,508 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of LivaNova by 140.0% in the 3rd quarter. Marshall Wace LLP now owns 350,899 shares of the company’s stock worth $43,501,000 after purchasing an additional 204,684 shares in the last quarter. Hedge funds and other institutional investors own 86.53% of the company’s stock.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Recommended Story: Diversification
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.